Supply & License Agreement for First-Ever Point of Care Vet Cancer Screen

HSKA billboard in the city

Marshall Gerstein represented Volition Rx Limited in an exclusive global supply and licensing agreement with Heska Corporation to sell Volition’s Nu.Q® Vet Cancer Test. The transaction clears the way for the first cancer screening available at clinics and other points of care, opening a market for cancer screening and monitoring for dogs and cats estimated to be worth more than $11 billion. The $28 million transaction--$10 million upfront and up to $18 million based upon achieving near/mid-term milestones—advances Volition’s strategy to ensure the broadest possible accessibility to the Nu.Q® Test worldwide. Volition continues to make significant progress in ongoing negotiations with the multi-national veterinary companies to provide central lab global coverage for the Nu.Q® Test. The firm is also negotiating these strategic partnerships.

Offsite Notice

By clicking “Proceed” below, you will be opening a new browser window and leaving our website.